• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Clarus Therapeutics Holdings Inc. (Amendment)

    2/14/22 11:35:41 AM ET
    $CRXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRXT alert in real time by email
    SC 13G/A 1 lighthouse-bluwu123121a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    Clarus Therapeutics Holdings, Inc.

    (Name of Issuer)

     

    Common Stock, Par Value $.0001 Per Share

    (Title of Class of Securities)

     

    18271L107

    (CUSIP Number)

     

     

    December 31, 2021
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  18271L107
     SCHEDULE 13G/A
    Page 2 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Lighthouse Investment Partners, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
    TYPE OF REPORTING PERSON
     
    IA

     


     

    CUSIP No.  18271L107
     SCHEDULE 13G/A
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    MAP 136 Segregated Portfolio, a segregated portfolio of LMA SPC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
    TYPE OF REPORTING PERSON
     
    FI

     


     

    CUSIP No.  18271L107
     SCHEDULE 13G/A
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    MAP 214 Segregated Portfolio, a segregated portfolio of LMA SPC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    0
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    0
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    0%
    12
    TYPE OF REPORTING PERSON
     
    FI
     


     

     

    CUSIP No. 18271L107
     SCHEDULE 13G/A
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    Clarus Therapeutics Holdings, Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    555 Skokie Boulevard

    Suite 340, Northbrook, Illinois 60062

    Item 2.(a) Name of Person Filing:

     

    This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”)

     

    i) Lighthouse Investment Partners, LLC (“Lighthouse”) 

    ii) MAP 136 Segregated Portfolio, a segregated portfolio of LMA SPC (“MAP 136”)

    iii) MAP 214 Segregated Portfolio, a segregated portfolio of LMA SPC (“MAP 214”)

      

    This Statement relates to the Issuer’s shares of common stock (“Shares”) directly beneficially owned by MAP 136 and MAP 214. Lighthouse serves as the investment manager of MAP 136 and MAP 214. Because Lighthouse may be deemed to control MAP 136 and MAP 214, as applicable, Lighthouse may be deemed to beneficially own, and to have the power to vote or direct the vote of, and the power to direct the disposition of the Issuer’s Shares reported herein.

     

    Address of Principal Business Office:

    3801 PGA Boulevard, Suite 500, Palm Beach Gardens, FL 33410

     

    Citizenship:

    Each of MAP 136 and MAP 214 are segregated portfolios of LMA SPC, a Cayman Islands segregated portfolio company. Lighthouse is a Delaware limited liability company.

      

    Item 2.(d) Title of Class of Securities

    Common Stock, Par Value $.0001 Per Share

     

    Item 2.(e) CUSIP No.:

    18271L107

     

    CUSIP No.  18271L107
     SCHEDULE 13G/A
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 18271L107
     SCHEDULE 13G/A
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

    (a) Amount Beneficially Owned: As of December 31, 2021, each of the Reporting Persons may be deemed the beneficial owner of 0 Shares.

     

      (b) Percent of Class: As of December 31, 2021, each of the Reporting Persons may be deemed the beneficial owner of approximately 0% of Shares outstanding.

     

      (c) Number of shares to which the person has:

     

      (i) Sole power to vote or to direct the vote: 0

     

      (ii) Shared power to vote or to direct the vote: 0.

     

      (iii) Sole power to dispose or to direct the disposition of: 0

     

      (iv) Shared power to dispose or to direct the disposition of 0.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 18271L107
     SCHEDULE 13G/A
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2022

     

     

     

     

    Lighthouse Investment Partners, LLC

           
      By:  /s/ Robert P. Swan
        Robert P. Swan, Vice President
           
     

    MAP 136 Segregated Portfolio, a segregated portfolio of LMA SPC

           
      By:  /s/ Robert P. Swan
        Robert P. Swan, Director
           
     

    MAP 214 Segregated Portfolio, a segregated portfolio of LMA SPC

           
      By:  /s/ Robert P. Swan
        Robert P. Swan, Director
           

     
    CUSIP No. 18271L107
     SCHEDULE 13G/A
    Page 9 of 9 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: February 14, 2022

     

     

    Lighthouse Investment Partners, LLC

           
      By:  /s/ Robert P. Swan
        Robert P. Swan, Vice President
           
     

    MAP 136 Segregated Portfolio, a segregated portfolio of LMA SPC

           
      By:  /s/ Robert P. Swan
        Robert P. Swan, Director
           
     

    MAP 214 Segregated Portfolio, a segregated portfolio of LMA SPC

           
      By:  /s/ Robert P. Swan
        Robert P. Swan, Director
           
    Get the next $CRXT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CRXT

    DatePrice TargetRatingAnalyst
    10/13/2021$10.00Buy
    Truist Securities
    10/6/2021$12.00Buy
    Needham
    9/29/2021$13.00Buy
    Maxim Group
    More analyst ratings

    $CRXT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist Securities initiated coverage on Clarus Therapeutics Hldgs with a new price target

      Truist Securities initiated coverage of Clarus Therapeutics Hldgs with a rating of Buy and set a new price target of $10.00

      10/13/21 7:15:13 AM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham initiated coverage on Clarus Therapeutics Hldgs with a new price target

      Needham initiated coverage of Clarus Therapeutics Hldgs with a rating of Buy and set a new price target of $12.00

      10/6/21 6:00:16 AM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on Clarus Therapeutics with a new price target

      Maxim Group initiated coverage of Clarus Therapeutics with a rating of Buy and set a new price target of $13.00

      9/29/21 8:32:42 AM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRXT
    SEC Filings

    See more

    $CRXT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CRXT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SEC Form 15-12G filed by Clarus Therapeutics Holdings Inc.

      15-12G - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

      3/1/23 7:35:06 AM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clarus Therapeutics Holdings Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Other Events

      8-K - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

      3/1/23 7:26:43 AM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Clarus Therapeutics Holdings Inc.

      S-8 POS - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

      3/1/23 7:22:23 AM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Prygocki Mark A Sr was granted 1,922 shares, increasing direct ownership by 50% to 5,766 units

      4 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)

      6/9/22 8:06:00 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Murphy Kimberly M was granted 1,922 shares, increasing direct ownership by 50% to 5,766 units

      4 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)

      6/9/22 8:04:31 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Amory John Kenneth was granted 1,922 shares, increasing direct ownership by 50% to 5,766 units

      4 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)

      6/9/22 8:02:52 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful Bidder

      Court-supervised auction for JATENZO (testosterone undecanoate capsules; C-III) concluded on October 14, 2022 NORTHBROOK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC:CRXTQ), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that, subject to entry into definitive documentation, it and its wholly-owned subsidiary, Clarus Therapeutics, Inc., selected Tolmar, Inc., (Buffalo Grove, IL) as the winning bidder in a competitive bidding and auction proceeding for the sale of JATENZO (and certain related assets). The bidding and auction procedures were approved by the U. S. Ba

      10/18/22 4:05:00 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code

      NORTHBROOK, Ill., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that it, together with its wholly-owned subsidiary Clarus Therapeutics, Inc., has filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the Court). Clarus has also filed a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code of its sole commercial asset, JATENZO, that is approved for use by healthcare providers to treat testos

      9/5/22 10:19:04 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction

      Second quarter 2022 net revenue increased 46% year-over-year to $4.1 million Second quarter 2022 total prescription growth for JATENZO® increased 23% sequentially and increased 72% year-over-year Immediate reduction in workforce by approximately 40% of total headcount; transition of Chief Financial Officer role NORTHBROOK, Ill., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies, today reported financial results for the second quarter of 2022. Clarus also announced that it is pursuing an immediate reduction in staff as i

      8/18/22 4:05:07 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRXT
    Leadership Updates

    Live Leadership Updates

    See more
    • Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer

      Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including coronaviruses, announces the appointment of Ms. Kimberly M. Murphy, member of the Board of Directors, as President and Chief Executive Officer effective June 23, 2022. Ms. Murphy brings more than 25 years of vaccine industry experience at leading pharmaceutical companies including serving as a key leader in the successful US and Global launch of Merck's HPV/Gardasil Franchise. Ms. Murphy joined Oragenics' Board of Directors in 2020. "As a Board Member, Ms. Murphy's extensive experience in the vaccine industry has provided valuable insight for Oragenics' corporat

      6/23/22 4:30:00 PM ET
      $BWV
      $CRXT
      $OGEN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development Officer

      Dr. Jumadilova most recently led clinical development programs at Insmed and Pfizer and has nearly 30 years of combined pharmaceutical and biotech experience NORTHBROOK, Ill., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the appointment of Zhanna Jumadilova, M.D., M.B.A., as Chief Clinical Development Officer, effective January 17, 2022. Dr. Jumadilova has nearly 30 years of experience in the pharmaceutical and biotech industries. She most recently led clinical development programs

      1/18/22 9:05:00 AM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRXT
    Financials

    Live finance-specific insights

    See more
    • Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results

      NORTHBROOK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. ("Clarus") (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its first quarter 2022 financial and operating results on Monday, May 16, 2022, after the market closes. Clarus will host a conference call on Monday, May 16, 2022, at 5:15 p.m. ET to discuss the results. The dial-in numbers are (844) 249-2007 for domestic callers and (224) 619-3902 for international callers. The conference ID number is 7677008. A live webcast and replay of the conference call will be

      5/12/22 9:05:00 AM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clarus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

      2021 net revenue increased 119% year-over-year to $14.0 million Fourth quarter 2021 net revenue increased 88% year-over-year to $4.6 million Fourth quarter 2021 total prescription growth for JATENZO® increased 11% sequentially and increased 81% year-over-year Conference call and webcast today at 5:15 p.m. ET NORTHBROOK, Ill., March 30, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today reported financial results for the fourth quarter and full year of 2021. "Clarus delivered solid growth in net revenu

      3/30/22 4:05:00 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clarus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial and Operating Results

      NORTHBROOK, Ill., March 29, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. ("Clarus") (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its fourth quarter and full year 2021 financial and operating results on Wednesday, March 30, 2022, after the market closes. Clarus will host a conference call on Wednesday, March 30, 2022, at 5:15 p.m. ET to discuss the results. The dial-in numbers are (844) 249-2007 for domestic callers and (224) 619-3902 for international callers. The conference ID number is 5454819. A live webcast and replay of the

      3/29/22 4:05:00 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRXT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Clarus Therapeutics Holdings Inc. (Amendment)

      SC 13G/A - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)

      2/14/23 12:29:21 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Clarus Therapeutics Holdings Inc. (Amendment)

      SC 13G/A - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)

      7/6/22 4:00:10 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Clarus Therapeutics Holdings Inc. (Amendment)

      SC 13D/A - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)

      4/21/22 8:43:02 PM ET
      $CRXT
      Biotechnology: Pharmaceutical Preparations
      Health Care